| ￥3300 | |
| Z04717-100 | |
|
|
|
|
|
|
|
|
|
| Species | Canine | ||||
| Protein Construction |
|
||||
| Purity |
>?95%?as?determined?by?Bis?Tris?PAGE? >?95%?as?determined?by?HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 36.52 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 40-45 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of S100B hFc Chimera, Canine is greater than 95% as determined by SEC-HPLC. ?
S100B hFc Chimera, Canine on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. ?
| Target Background | S100B, a calcium-binding protein of the EF-hand type exerts both intracellular and extracellular functions.The intracellular, and extracellular, roles of S100B are attractive therapeutic targets for the treatment of both cardiac and vascular disease. |
| Synonyms | Protein S100; S100 calcium-binding; NEF; S100; 100beta; S100-B |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
